MedTrace Logo

Management of Epistaxis Comparing Nasal Packing Versus Greater Palatine Foramen Block

NCT07421622 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-24

No results posted yet for this study

Summary

The goal of this pilot randomized controlled trial is to compare pain relief efficacy while using nasal packing versus greater palatine foramen block (GPFB) in the management of acute episodes of epistaxis. The main questions it aims to answer are: Does GPFB have less potential to inflict pain when dealing with hemostasis with epistaxis, utilizing a pre-validated 10-point visual analog scale (VAS)? Was hemostasis management more effective in either technique? Researchers will compare anterior nasal packing to greater palatine foramen block using 2% xylocaine with adrenaline.

Patients will receive any of the hemostatic interventions at the time of the acute epistaxis episode.

The questionnaire will be administered 24 hours post-intervention.

Conditions

  • Epistaxis Nosebleed
  • Greater Palatine Foramen

Interventions

PROCEDURE

Greater Palatine Foramen Block with 2% xylocaine with adrenaline

Patients allocated to this group will receive a greater palatine foramen block using a local anaesthetic agent (2% i.e. 20mg/dL Inj. Lidocaine with adrenaline) administered at the greater palatine foramen under aseptic conditions. Patients will be monitored for local anaesthetic as well as GPF block-related adverse effects. Hemostasis will be assessed following the procedure.

PROCEDURE

Anterior Nasal Packing

Patients allocated to this group will receive anterior nasal packing using standard non-absorbable nasal packs following institutional protocol. Packs will remain in situ for 24-72 hours, unless earlier removal is clinically indicated.

Sponsors & Collaborators

  • Sheikh Zayed Federal Postgraduate Medical Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2027-02-28
Completion
2027-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07421622 on ClinicalTrials.gov